相似文献
1
The use of olanzapine for movement disorder in Huntington's disease: a first case report.
J Neurol Neurosurg Psychiatry. 1999 Jul;67(1):123-4. doi: 10.1136/jnnp.67.1.123.
2
Olanzapine and Huntington's disease.
J Clin Psychopharmacol. 2001 Apr;21(2):245-6. doi: 10.1097/00004714-200104000-00023.
3
Improvement of Huntington's disease with olanzapine and valproate.
N Engl J Med. 2000 Sep 28;343(13):973-4. doi: 10.1056/NEJM200009283431316.
4
Brain SPECT imaging in Huntington's disease before and after therapy with olanzapine. Case report.
Arq Neuropsiquiatr. 1999 Sep;57(3B):863-6. doi: 10.1590/s0004-282x1999000500021.
5
Olanzapine for Huntington's disease: an open label study.
Clin Neuropharmacol. 2002 Sep-Oct;25(5):263-5. doi: 10.1097/00002826-200209000-00007.
6
High-dose olanzapine in Huntington's disease.
Int Clin Psychopharmacol. 2002 Mar;17(2):91-3. doi: 10.1097/00004850-200203000-00009.
7
Riluzole and olanzapine in Huntington's disease.
Eur J Neurol. 2002 Mar;9(2):183-4. doi: 10.1046/j.1468-1331.2002.0354f.x.
8
Rapid onset of tardive dyskinesia in Huntington disease with olanzapine.
J Clin Psychopharmacol. 2002 Aug;22(4):438-9. doi: 10.1097/00004714-200208000-00020.
9
Olanzapine-associated seizure.
Ann Pharmacother. 2003 Jan;37(1):149-50. doi: 10.1345/aph.1C288.
10
[Olanzapine improves chorea in patients with Huntington's disease].
Rev Neurol. 2002;35(6):524-5.
引用本文的文献
1
Update on the Symptomatic Treatment of Huntington's Disease: From Pathophysiology to Clinical Practice.
Int J Mol Sci. 2025 Jun 27;26(13):6220. doi: 10.3390/ijms26136220.
2
Exploring molecular mechanisms, therapeutic strategies, and clinical manifestations of Huntington's disease.
Arch Pharm Res. 2024 Jun;47(6):571-595. doi: 10.1007/s12272-024-01499-w. Epub 2024 May 19.
3
State-of-the-art pharmacological approaches to reduce chorea in Huntington's disease.
Expert Opin Pharmacother. 2021 Jun;22(8):1015-1024. doi: 10.1080/14656566.2021.1876666. Epub 2021 Feb 8.
4
Rutin as a Potent Antioxidant: Implications for Neurodegenerative Disorders.
Oxid Med Cell Longev. 2018 Jun 27;2018:6241017. doi: 10.1155/2018/6241017. eCollection 2018.
5
Current Pharmacological Approaches to Reduce Chorea in Huntington's Disease.
Drugs. 2017 Jan;77(1):29-46. doi: 10.1007/s40265-016-0670-4.
6
Olanzapine inhibits proliferation, migration and anchorage-independent growth in human glioblastoma cell lines and enhances temozolomide's antiproliferative effect.
J Neurooncol. 2015 Mar;122(1):21-33. doi: 10.1007/s11060-014-1688-7. Epub 2014 Dec 19.
7
Treatment of Huntington's disease.
Neurotherapeutics. 2014 Jan;11(1):153-60. doi: 10.1007/s13311-013-0244-z.
8
Treatment of huntington disease.
Curr Treat Options Neurol. 2013 Aug;15(4):424-38. doi: 10.1007/s11940-013-0219-8.
9
Tetrabenazine: the first approved drug for the treatment of chorea in US patients with Huntington disease.
Neuropsychiatr Dis Treat. 2010 Oct 5;6:657-65. doi: 10.2147/NDT.S6430.
10
Advances in the pharmacological management of Huntington's disease.
Drugs. 2010 Mar 26;70(5):561-71. doi: 10.2165/11534430-000000000-00000.
Zotero 插件